How the Big 6 vaccine makers stack up to one another: Source ESPN: The Big Six manufacturers of Cervarix, Merck, and Pfizer are among the most successful in the industry.
They are the largest producers of generic versions of the vaccines, which are also available in multiple forms.
They have received an average of $2.7 billion for each of the six vaccines, according to the Merck and Pfiser press releases.
Each manufacturer has also received $1.8 billion from the federal government for each vaccine.
The most successful vaccine makers are Pfizer, which received $3.6 billion, Merks $3 billion, and AstraZeneca $2 billion.
The top five vaccines that received the most government funding were Merck’s hepatitis B vaccine ($2.8B), Astra Zeneca’s pneumococcal vaccine ($1.5B), Pfizer’s varicella vaccine ($975M), Pfizers own pneumococcus vaccine ($925M), and Astrazeneca’s rubella vaccine ($845M).
Pfizer is the largest vaccine maker of the Big 12, which is a merger of the Pac-12 Conference.
In addition, Merkel has an 8.6 percent share of the industry, and she is expected to become chancellor of the European Union in 2019.
All six vaccine makers have also received nearly $5 billion in taxpayer-funded research funding.
This comes after the federal Department of Health and Human Services last year announced it was going to cancel $100 million in funding for research and development for new vaccines that would have been produced by the companies.
These are not the first times that the Big six have faced criticism for their vaccine production practices.
Pfizer was found to be in violation of federal food safety regulations when they withheld millions of doses of the company’s toxoplasmosis vaccine in the early 1990s and had to pay $2 million in fines.
The company was ordered to stop manufacturing toxoplasma toxin vaccines for two years, but they were allowed to continue production and to sell the toxoplasms to other companies.